A/DT new/JJ drug/NN 0/-NONE- *T*-2/-NONE- to/TO prevent/VB the/DT rejection/NN of/IN transplanted/JJ organs/NNS has/VBZ been/VBN successfully/RB used/VBN *-1/-NONE- on/IN more/JJR than/IN 100/CD patients/NNS at/IN the/DT University/NNP of/IN Pittsburgh/NNP ,/, according/VBG to/TO researchers/NNS ./.
The/DT drug/NN ,/, which/WDT *T*-2/-NONE- is/VBZ still/RB in/IN the/DT experimental/JJ phase/NN ,/, has/VBZ n't/RB been/VBN approved/VBN *-1/-NONE- yet/RB by/IN the/DT Food/NNP and/CC Drug/NNP Admistration/NNP ,/, and/CC its/PRP$ long-term/JJ effects/NNS are/VBP unknown/JJ ./.
But/CC researchers/NNS say/VBP 0/-NONE- the/DT drug/NN ,/, called/VBN */-NONE- FK-506/NNP ,/, could/MD revolutionize/VB the/DT transplantation/NN field/NN by/IN */-NONE- reducing/VBG harmful/JJ side/JJ effects/NNS and/CC by/IN */-NONE- lowering/VBG rejection/NN rates/NNS ./.
Rejection/NN has/VBZ been/VBN the/DT major/JJ obstacle/NN in/IN the/DT approximately/RB 30,000/CD organ/NN transplants/NNS performed/VBN */-NONE- world-wide/RB each/DT year/NN ./.
Researchers/NNS began/VBD *-2/-NONE- using/VBG the/DT drug/NN *ICH*-3/-NONE- in/IN February/NNP on/IN patients/NNS who/WP *T*-1/-NONE- had/VBD received/VBN kidney/NN ,/, liver/NN ,/, heart/NN and/CC pancreas/NN transplants/NNS ./.
Only/RB two/CD of/IN 111/CD transplants/NNS have/VBP been/VBN rejected/VBN *-1/-NONE- ./.
The/DT drug/NN ,/, discovered/VBN */-NONE- in/IN 1984/CD ,/, is/VBZ metabolized/VBN *-1/-NONE- from/IN soil/NN fungus/NN found/VBN */-NONE- in/IN Japan/NNP ./.
The/DT Pittsburgh/NNP patients/NNS are/VBP the/DT first/JJ humans/NNS 0/-NONE- *T*-4/-NONE- to/TO be/VB given/VBN *-1/-NONE- the/DT drug/NN ,/, which/WDT *T*-3/-NONE- is/VBZ made/VBN *-2/-NONE- by/IN Fujisawa/NNP Pharmaceutical/NNP Co/NNP ./.
``/`` We/PRP 're/VBP shocked/JJ by/IN it/PRP ,/, because/IN it/PRP 's/VBZ worked/VBN so/RB fast/RB ,/, ''/'' said/VBD *T*-1/-NONE- Dr./NNP Thomas/NNP E./NNP Starzl/NNP ,/, director/NN of/IN the/DT University/NNP of/IN Pittsburgh/NNP Transplantation/NNP Program/NNP ,/, at/IN a/DT news/NN conference/NN here/RB yesterday/NN ./.
``/`` We/PRP consider/VBP it/PRP a/DT life-saving/JJ drug/NN ,/, like/IN one/CD for/IN AIDS/NNP ,/, ''/'' said/VBD *T*-1/-NONE- Dr./NNP John/NNP Fung/NNP ,/, an/DT immunologist/NN at/IN the/DT University/NNP of/IN Pittsburgh/NNP ./.
Researchers/NNS say/VBP 0/-NONE- they/PRP believe/VBP 0/-NONE- FK-506/NNP is/VBZ 100/CD times/NNS more/RBR effective/JJ than/IN the/DT traditional/JJ anti-rejection/JJ drug/NN ,/, cyclosporine/NN ,/, made/VBN */-NONE- by/IN Swiss/JJ pharmaceutical/JJ giant/NN Sandoz/NNP Ltd/NNP ./.
They/PRP are/VBP also/RB encouraged/VBN *-1/-NONE- by/IN the/DT relatively/RB mild/JJ side/JJ effects/NNS of/IN FK-506/NNP ,/, compared/VBN with/IN cyclosporine/NN ,/, which/WDT *T*-507/-NONE- can/MD cause/VB renal/JJ failure/NN ,/, morbidity/NN ,/, nausea/NN and/CC other/JJ problems/NNS ./.
``/`` The/DT side/JJ effects/NNS -LCB-/-LRB- of/IN cyclosporine/NN -RCB-/-RRB- have/VBP made/VBN the/DT penalty/NN for/IN its/PRP$ success/NN rather/RB high/JJ ,/, ''/'' Dr./NNP Starzl/NNP said/VBD *T*-1/-NONE- ./.
Dr./NNP Fung/NNP said/VBD that/IN FK-506/NNP would/MD not/RB be/VB available/JJ in/IN the/DT market/NN for/IN at/IN least/JJS a/DT year/NN ,/, and/CC that/IN the/DT FDA/NNP approval/NN process/NN usually/RB takes/VBZ three/CD years/NNS to/TO five/CD years/NNS ./.
There/EX are/VBP no/DT firm/JJ plans/NNS */-NONE- to/TO expand/VB the/DT experimental/JJ program/NN beyond/IN the/DT University/NNP of/IN Pittsburgh/NNP ,/, whose/WP$ hospital/NN *T*-1/-NONE- performs/VBZ the/DT most/JJS transplants/NNS in/IN the/DT world/NN ./.
Researchers/NNS could/MD n't/RB estimate/VB the/DT cost/NN of/IN the/DT drug/NN when/WRB it/PRP reaches/VBZ the/DT market/NN *T*-1/-NONE- ,/, but/CC they/PRP said/VBD 0/-NONE- FK-506/NNP will/MD enable/VB patients/NNS to/TO cut/VB hospital/NN stays/NNS by/IN 50/CD %/NN and/CC reduce/VB the/DT number/NN of/IN blood/NN tests/NNS used/VBN */-NONE- to/TO monitor/VB the/DT dosage/NN of/IN cyclosporine/JJ and/CC other/JJ drugs/NNS among/IN transplant/NN recipients/NNS ./.
Dr./NNP Starzl/NNP said/VBD 0/-NONE- the/DT research/NN has/VBZ been/VBN largely/RB financed/VBN *-1/-NONE- by/IN the/DT National/NNP Institute/NNP of/IN Health/NNP and/CC by/IN university/NN funds/NNS ,/, and/CC that/IN Fujisawa/NNP did/VBD n't/RB give/VB the/DT hospital/NN any/DT grants/NNS ./.
He/PRP said/VBD that/IN the/DT research/NN team/NN had/VBD no/DT financial/JJ stake/NN in/IN the/DT drug/NN ./.
``/`` We/PRP 've/VBP known/VBN for/IN six/CD months/NNS the/DT effect/NN of/IN this/DT drug/NN ,/, and/CC our/PRP$ advice/NN to/TO our/PRP$ people/NNS has/VBZ been/VBN */-NONE- not/RB to/TO buy/VB the/DT company/NN 's/POS stock/NN ,/, ''/'' Dr./NNP Starzl/NNP said/VBD *T*-2/-NONE- ,/, *-1/-NONE- adding/VBG that/IN */-NONE- profiting/VBG from/IN FK-506/NNP would/MD n't/RB be/VB ethical/JJ ./.

